Optimization of a pyrazolo[1,5-a]pyrimidine class of KDR kinase inhibitors:: Improvements in physical properties enhance cellular activity and pharmacokinetics

被引:79
作者
Fraley, ME [1 ]
Rubino, RS
Hoffman, WF
Hambaugh, SR
Arrington, KL
Hungate, RW
Bilodeau, MT
Tebben, AJ
Rutledge, RZ
Kendall, RL
McFall, RC
Huckle, WR
Coll, KE
Thomas, KA
机构
[1] Merck Res Labs, Dept Med Chem, West Point, PA 19486 USA
[2] Merck Res Labs, Dept Canc Res, West Point, PA 19486 USA
关键词
D O I
10.1016/S0960-894X(02)00827-2
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
We have introduced solubilizing functionality to a 3,6-disubstituted pyrazolo[1,5-a]pyrimidine series of KDR kinase inhibitors to improve the physical properties of these compounds. The addition of a basic side-chain to the 6-aryl ring, introduction of 3-pyridyl groups, and most significantly, incorporation of a 4-pyridinonyl substituent at the 6-position of the core are modifications that maintain and often enhance the intrinsic potency of this class of inhibitors. Moreover, the improvements in physical properties result in marked increases in cellular activity and more favorable pharmacokinetics in rats. The synthesis and SAR of these compounds are described.(C) 2002 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:3537 / 3541
页数:5
相关论文
共 26 条
  • [1] SYNTHESIS AND SECRETION OF VASCULAR-PERMEABILITY FACTOR VASCULAR ENDOTHELIAL GROWTH-FACTOR BY HUMAN RETINAL-PIGMENT EPITHELIAL-CELLS
    ADAMIS, AP
    SHIMA, DT
    YEO, KT
    YEO, TK
    BROWN, LF
    BERSE, B
    DAMORE, PA
    FOLKMAN, J
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1993, 193 (02) : 631 - 638
  • [2] Kinase insert domain-containing receptor kinase inhibitors as anti-angiogenic agents
    Bilodeau, MT
    Fraley, ME
    Hartman, GD
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2002, 11 (06) : 737 - 745
  • [3] Angiogenesis in cancer and other diseases
    Carmeliet, P
    Jain, RK
    [J]. NATURE, 2000, 407 (6801) : 249 - 257
  • [4] The role of VEGF and thrombospondins in skin angiogenesis
    Detmar, M
    [J]. JOURNAL OF DERMATOLOGICAL SCIENCE, 2000, 24 : S78 - S84
  • [5] Drevs J, 2000, CANCER RES, V60, P4819
  • [6] ANGIOGENESIS IN CANCER, VASCULAR, RHEUMATOID AND OTHER DISEASE
    FOLKMAN, J
    [J]. NATURE MEDICINE, 1995, 1 (01) : 27 - 31
  • [7] Fong TAT, 1999, CANCER RES, V59, P99
  • [8] Synthesis and initial SAR studies of 3,6-disubstituted pyrazolol[1,5-a]pyrimidines:: A new class of KDR kinase inhibitors
    Fraley, ME
    Hoffman, WF
    Rubino, RS
    Hungate, RW
    Tebben, AJ
    Rutledge, RZ
    McFall, RC
    Huckle, WR
    Kendall, RL
    Coll, KE
    Thomas, KA
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2002, 12 (19) : 2767 - 2770
  • [9] The angiogenic pathway 'vascular endothelial growth factor/flk-I (KDR)-receptor' in rheumatoid arthritis and osteoarthritis
    Giatromanolaki, A
    Sivridis, E
    Atanassou, N
    Zois, E
    Thorpe, PE
    Brekken, RA
    Gatter, KC
    Harris, AL
    Koukourakis, IM
    Koukourakis, MI
    [J]. JOURNAL OF PATHOLOGY, 2001, 194 (01) : 101 - 108
  • [10] One pot biaryl synthesis via in situ boronate formation
    Giroux, A
    Han, YX
    Prasit, P
    [J]. TETRAHEDRON LETTERS, 1997, 38 (22) : 3841 - 3844